

12/28/98



Box Seq PATENT

A

Attorney Docket No. WAKAB37.001AUS

Date: December 28, 1998

Page 1

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

ATTENTION: APPLICATION BRANCH

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Takashi Tsuruo, Naasani Imad, Hiroyuki Seimiya, and Haruo Sugano

For: **TELOMERASE INHIBITOR**

Enclosed are:

- (X) Four (4) sheet(s) of drawing.
- (X) Preliminary Amendment in three (3) pages with Sequence Listing in two (2) pages.
- (X) Diskette for Sequence Listing.
- (X) Recordation form cover sheet with 3-page assignment.
- (X) **SIGNED** Declaration and Power of Attorney by the inventor(s).
- (X) Return prepaid postcard.

CLAIMS AS FILED

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee			\$760	\$760
Total Claims	14 - 20 =	0 ×	\$18	\$0
Independent Claims	4 - 3 =	1 ×	\$78	\$78
TOTAL FILING FEE				\$838

- (X) A check in the amount of \$838.00 to cover the filing fee is enclosed.
- (X) A check in the amount of \$40.00 to cover the assignment recording fee.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 11-1410. A duplicate copy of this sheet is enclosed.
- (X) Please use Customer No. 20,995 for the correspondence address.

Daniel E. Altman
Daniel E. Altman
Registration No. 34,115
Attorney of Record

KOA-8465 hr
121598

jc549 U.S. PTO
09/22/931
12/28/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Tsuruo, et al.)	Group Art Unit Unknown
)	
Serial No.	:	Unknown)	
)	
Filed	:	Herewith)	
)	
For	:	TELOMERASE INHIBITOR)	
)	
Examiner	:	Unknown)	
)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-captioned application, please amend the application as follows:

IN THE SEQUENCE LISTING:

Please insert the attached sequence listing having page numbers 17-18 after page 16 of the specification. Thereafter, please renumber pages 17-19 as pages 19-21.

IN THE CLAIMS:

Please amend the claims as follows:

In the first line of Claim 3, please delete "or 2".

Serial No. : Unknown
Filed : Herewith

In the first line of Claim 4, please delete ", 2, or 3".

In the first line of Claim 5, please delete "either one of claims 1 to 4" and insert --Claim 1-- therefor.

In the first line of Claim 8, please delete "or 7".

In the first line of Claim 9, please delete ", 7, or 8".

In the first line of Claim 10, please delete "either one of claims 6 to 9" and insert --Claim 6-- therefor.

In the second line of Claim 11, please delete "any one of claims 1 to 5" and insert --Claim 1-- therefor.

In the third line of Claim 12, please delete "any one of claims 6 to 10" and insert --Claim 6-- therefor.

Please cancel Claims 13 and 14.

Statement Under 37 C.F.R. §1.821(f)

A printed copy of the Sequence Listing required by 37 C.F.R. §1.821(c) and a copy of the Sequence Listing in computer readable form required by 37 C.F.R. §1.821(e) are submitted herewith. All of the nucleotide in the attached Sequence Listing were included in the application as filed. No new matter is being added herewith.

As required under 37 C.F.R. §1.821(f), the information recorded in computer readable form is identical to the written Sequence Listing.

Serial No. : Unknown
Filed : Herewith


REMARKS

The amendments requested herein are requested solely in order to adapt the application to U.S. practice, and the cancellations of recitations in the claims have been made without prejudice. As such, these amendments do not constitute the addition of new matter to the application, and entry of the amendments is respectfully requested.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 28, 1998

By: 
Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

SPECIFICATION

Title of the Invention

TELOMERASE INHIBITOR

Background of the Invention

1. Field of the Invention

The present invention relates to a telomerase inhibitor which uses catechins as an effective component and is useful as a cancer prevention agent, anticancer agent, agent to delay cancer progression, or the like.

2. Description of the Related Art

Various surgical, internal and, radiological antineoplastic procedures, and combinations thereof have been developed for the treatment of cancer. Extensive investigations are also being done to prevent cancer or on prophylactic means to regard the progression of a cancer as much as possible so as to prevent its transition to the fatal stage. Yet in all cases, it is evident that a further understanding as to the mechanism of the genesis and progression of cancers is essential in order to develop effective methods for their prevention and treatment.

Recently, the presence of an enzyme called telomerase has drawn attention as a new target in cancer therapy. This telomerase, a reverse transcriptase, synthesizes the telomeric DNA (hereinafter referred to as telomere) which is involved in the stabilization of a chromosome during cell growth. This telomere is a segment composed of a linear DNA at the end of the chromosome, and the presence of the telomere stabilizes the chromosome itself and prevents aberrations caused by binding between chromosomes.

Research has revealed that telomeres in human tissues are shortened with age, and that cells die as this shortening progresses; thus the involvement of telomeres

with the aging process and cell division cycle has become clear. Furthermore, it has been reported that telomeres in cancer cells are shorter than those in surrounding normal cells, which has further drawn attention to the telomere as an interesting target in cancer research.

Moreover, it has been reported that activity of telomerase, a telomere-synthesizing enzyme, was detected in cells of 85% of all cancers (for example, Kim, N.W. et al., *Science*, 266, 2011-2015, 1994; Healy, K.C., *Oncol. Res.*, 7, 121-130, 1995; Raymond, E. et al., *Biotechnology*, 7, 583-591, 1996). In contrast, almost all normal somatic cells are known to be telomerase negative. On the basis of these observations, telomere and telomerase have drawn further attention as potential targets in cancer treatment.

Meanwhile, effect of tea in the prevention and control of cancer is being studied. Yang et al. (Yang, C.S. and Wang, Z-Y., *J. Natl. Cancer Inst.*, 85, 1038-1049, 1993) and Fujiki et al. (Fujiki, H. et al., *Nutrition Reviews*, 54, 67-70, 1996) discussed the anticancer activity of green tea from the epidemiological point of view in their review articles. Furthermore, Liao et al. (Liao, S. et al., *Cancer Letter*, 96, 239-243, 1995) reported that epigallocatechin gallate (EGCG) contained in tea effectively suppressed cancer cell growth in nude mice with experimentally-induced tumors. Further, Taniguchi et al. (Taniguchi, S. et al., *Cancer Letters*, 65, 51-54, 1992) reported that oral administration of EGCG suppressed metastasis of malignant melanoma cells. However, none of these reports described the mechanisms underlying these effects of green tea or EGCG on cancer. In particular, these reports did not mention the effects of green tea or EGCG on telomerase, or the mechanism of anticancer activity associated with telomerase.

Although the utility of a telomerase inhibitor in cancer treatment could be surmised based on the hypothesis that the inhibition of telomerase activity in a cancer cell renders its chromosome less stable thereby shortening the life span of the cancer

cell. However, there are no reports to date regarding a substance which has an effective telomerase inhibiting activity and properties satisfactory for pharmaceutical use. Nor is there a reported case in the life span of cancer cell was effectively shortened by the use of a telomerase inhibitor.

Summary of the Invention

The object of the present invention is to provide a telomerase inhibitor having telomerase inhibiting activity, which is useful in providing an understanding of not only the involvement of telomere and telomerase with cancer, but also its prevention and treatment, whereby the telomerase inhibitor has the safe and appropriate properties for pharmaceutical use.

A telomerase inhibitor of the present invention is characterized in using or containing catechins as an effective component. A telomerase inhibitor of the present invention can be used as a reagent for use in various experiments on telomerase inhibition per se or those involving telomerase inhibition, and further as a cancer prevention agent, anticancer agent, or the like by preparing it in a pharmaceutical preparation. Further, by using a telomerase inhibitor of the present invention, the life span of cancer cells can be shortened to kill the cells, or the progression of cancer can be effectively controlled by arresting its growth and malignancy.

Catechins used in the present invention have unconventionally strong telomerase inhibiting activity, and can provide a telomerase inhibitor which is useful in providing an understanding of the involvement of telomerase with a cancer, and its prevention and treatment, and which possesses the safe and appropriate properties for pharmaceutical use.

Brief Description of the Drawings

Figure 1 shows the telomerase activity of different compounds.

Figure 2 shows changes in telomerase activity as a function of EGCG

concentration.

Figure 3 shows a Dixon plot for the telomerase inhibiting activity of EGCG.

Figure 4 shows the telomerase inhibiting activity of EGCG in a cell.

Figure 5 shows the effect of EGCG on cell growth.

Figure 6 shows the effect of EGCG on cell growth.

Figure 7 shows the distribution of TRF lengths from HT29 cells at PD67 to PD70 in subcultures in the presence or absence of EGCG (15 μ M).

Detailed Description of the Invention and Preferred Embodiments

Commercially available catechins, or catechins extracted and isolated from tea by a known method can be used as an effective component of a telomerase inhibitor of the present invention.

Catechins from tea can be extracted and isolated, for example, by extracting tea leaves with hot water or a hydrophilic organic solvent, removing caffeine from the extract by extraction with chloroform, then further extracting with an organic solvent such as ethyl acetate to obtain a tea-catechin mixture, and finally isolating the catechins from this mixture by column chromatography using a hydrophilic organic solvent such as acetone as the eluant.

For example, extracts extracted from green tea, which contain catechins, or crude or purified products prepared from such extracts can be used. An example of a green tea extract is THEA-FLAN 90S (product name, ITO EN, Ltd).

Such catechins from tea can be isolated, for example, by methods described in Japanese Patent Laid-open (Kokai) No. 182479/92, Japanese Patent Laid-open (Kokai) No. 182480/92, Japanese Patent Laid-open (Kokai) No. 9607/94, Japanese Patent Laid-open (Kokai) No. 70105/75, and Japanese Patent No. 2703241.

Further, a green tea extract prepared as follows can also be used. First, leaves and stems of green tea plant are extracted with hot water to fractionate an extract, then this extract is concentrated while separating the solids, if necessary.

Concentration can be appropriately done under vacuum. The concentrate thus obtained is sterilized by heating, if necessary, then dried for use as a catechin-containing extract. Spray drying is appropriately used. Undried material can also be used, but the dried powder is preferable because of its ease-of-handling and improved preservability.

A green tea extract containing at least 35% by weight, preferably at least 90% by weight tea polyphenols and at least 10% by weight, preferably at least 40% by weight (-) epigallocatechin gallate can appropriately be used. Further, the caffeine content in the extract is preferably 10% or less than 10% by weight. The catechin content in the extract can be increased with the level of purification, which can be chosen as a function of the intended use. Catechins in the extract can be purified by an appropriate combination of a conventional extracting process, isolation process, column chromatography, and the like.

Examples of catechins to be used in the present invention include (-) epigallocatechin gallate (EGCG), (-) epigallocatechin (EGC), (-) epicatechin gallate (ECG), (-) epicatechin (EC) and (+)catechin. Derivatives of these catechins can also be used to the extent that efficacy of the present invention can be attained. Two or more of these catechins in combination can also be used. Of these catechins, epigallocatechin and epicatechin gallate are preferable, and epigallocatechin gallate is particularly preferable.

A telomerase inhibitor of the present invention can be prepared by incorporating a catechin as an effective component into an appropriate solvent, if necessary. Commercial catechins or highly-purified catechins obtained by extraction from tea can best be used by incorporating the catechin into an oil-in-water (O/W) emulsion, prepared, for example by mixing the catechin with a vegetable oil, emulsifying agent (e.g., Tween or Emulgene), and ascorbic acid (antioxidant), then lyophilizing the resulting emulsion. This emulsion is expected to permit a better

intestinal absorption of catechins, thus a more potent antitelomerase effect. An example of the composition before lyophilization is 5% by weight vegetable oil, emulsifying agent, or the like, 0.1% by weight antioxidant, and 5% by weight catechin. A preferable catechin content in the inhibitor after lyophilization is preferably 90-95% by weight. The inhibitor can be diluted for use, if necessary.

Further, when the abovementioned tea extract is used, the extract itself or the extract with an addition of an appropriate solvent can be used to obtain a telomerase inhibitor of the present invention. If an extract is used, the dried powder is preferable.

A pharmaceutical composition which contains a catechin having telomerase inhibiting activity as an active component can appropriately be used as a cancer prevention agent or carcinostatic agent. The carcinostatic effect includes the anticancer effect by which cancer cells are directly attacked, the effect by which the progression of cancer (malignancy) is retarded, or the like. A pharmaceutical composition having a catechin as an effective component can be formulated into various forms suited for the purpose of the treatment, by a conventional method using pharmaceutically acceptable carriers, diluents, or the like. Examples of such forms of pharmaceutical compositions include solid formulations such as tablets, pills, dispersible powders, granules, capsules, and suppositories, liquid formulations such as injections, suspensions, syrups, and emulsions, and semi-solid formulations such as plasters.

The amount of a catechin used in a pharmaceutical composition as an effective component can be, for example, 100 to 500 mg (approximately 90 to 95% by weight of the composition) for a tablet or capsule if a commercially available catechin or a purified preparation is used. A tea extract can be used without further purification in certain formulations, or it can be formulated into various forms suited to the intended treatment, by a conventional method using pharmaceutically acceptable

carriers, diluents, or the like in addition to the extract.

The dosage of a catechin used in a pharmaceutical composition can conveniently be determined as a function of the intended treatment, the nature of the condition being treated, or the like. For example, the dosage for adults can be in the range of about 500 to 2000 mg per day as the amount of effective chemical component, but it is not so restricted. Furthermore, the abovementioned lyophilized O/W emulsion can appropriately be used as a formulation or as a material for formulations.

Furthermore, various additives conventionally used in formulations can be incorporated in the pharmaceutical formulation of the present invention within a range so as not to inhibit the desired action of the catechin. Moreover, a telomerase inhibitor of the present invention could be rendered even more effective in the treatment of cancer by the co-administration of a chemotherapeutic agent (anticancer agent) to the cancer cells being attacked by the telomerase inhibitor.

A catechin, the effective component of the telomerase inhibitor of the present invention, can be obtained from tea components, is very safe, shows an effective activity in a small amount, and is very appropriate for use as a drug, particularly for the prevention or treatment of cancers in which telomerase is expressed.

The present invention will be further illustrated by the following examples. Unless otherwise stated, “%” means “% by weight.”

Production Example 1

Green tea leaves (20 g) were immersed in 300 ml of hot water (60°C) for 15 minutes for extraction. The extract was then filtered and the filtrate was concentrated at 40°C under vacuum using a rotary evaporator. After concentrating to about 40 ml, the resulting fluid was centrifuged (3,000 rpm, 10 minutes), and the supernatant thus obtained was lyophilized to obtain a pale brown dried powder (4.7 g) (powder sample 1).

Results of analysis as to the content of polyphenol, catechins, and other components contained in the dried powder thus obtained were as follows:

Tea polyphenols	41.5% by weight
(-)-Epigallocatechin gallate	15.1% by weight
(-)-Epigallocatechin	6.6% by weight
(-)-Epicatechin gallate	3.5% by weight
(-)-Epicatechin	2.3% by weight
Caffein	7.3% by weight

Example 1

Measurement of telomerase inhibiting activity in cell-free system

Telomerase inhibiting activity of EGCG, EGC, ECG, and EC (all products of Sigma) was measured according to the Telomeric Repeat Amplification Protocol (TRAP) method described by Kim et al. (Kim, N.W. et al., Science, 266, 2011-2015, 1994) as follows:

(1) Preparation of cell extract

Cells were washed with ice-cold PBS (phosphate buffered saline) and suspended again in PBS to count the cells. After centrifuging this cell suspension, the resulting cell mass was suspended in a TRAP assay buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl₂, 1 mM EDTA, 0.5% CHAPS, 10% glycerine, 5 mM 2-mercaptoethanol, and 0.1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochlorine), then the suspension was quick-frozen with liquid nitrogen. After melting, the suspension was allowed to stand in an ice bath for 30 minutes for extraction, then the resulting extract was centrifuged to obtain the supernatant as a cell extract for activity measurement.

(2) Reaction and treatment after reaction

A test compound, TS primer (50 ng), 50 μ M dNTPs, and T4g32 protein (Behringer-Manheim) were added to a specified volume of the cell extract

(corresponding to 200 to 1000 cells), and the admixture was incubated at 20°C for 30 minutes. After reaction, CX primer (100 ng) and an internal standard for PCR, ITAS (10^{-18} g), were added to the reaction solution, then PCR was performed in the presence of AmpliTaq DNA polymerase (2 U), i.e., (94°C, 40 seconds → 50°C, 40 seconds → 72°C, 60 seconds) x 30 cycles → 72°C, 2 minutes, to obtain PCR products.

Base sequences of the primers used in the abovementioned procedure are as follows:

TS primer:

5'-AATCCGTCGAGCAGAGTT-3' (SEQ ID NO: 1)

CX primer:

5'-GTGCCCTTAACCCTTACCCTTACCCTAA-3' (SEQ ID NO: 2)

ITAS:

5'AATCCGTCGAGCAGAGTTGTGAATGAGGCCTTCGAGGCTCTGAAG
AGAAGCACCCTGCTCAACCCCAACCAGCGGCTGCCTAAGGTGGAGATCCT
GCGCAGTGCCATCCAGTACATTGAGCGCCTATTAGGGTAAGGGTAAGGGT
AAGGG-3' (SEQ ID NO: 3)

In the in vitro reaction system, telomerase performs addition synthesis of telomere at the 3' end of the TS primer. Of the 24 bases at the 3'-end side of the CX primer, 21 bases are identical to a telomere sequence, hence the telomere product can be amplified by PCR with a combination of TS primer and CX primer. The 5' end part and the 3' end part of the ITAS sequence are made identical to the TS primer sequence and the CX primer sequence, respectively.

(3) Detection and quantitative analysis of reaction products

The PCR products obtained in the abovementioned procedure were resolved by polyacrylamide gel electrophoresis and the resulting DNA bands stained with SYBR Green (Takara Shuzo) were detected by irradiation with a UV transilluminator.

The detected bands were photographed. The intensity of each band was quantitatively analyzed using the NIH Image 1.60 software program. Telomerase activity was expressed as the intensity of a sample band relative to that of the band corresponding to the ITAS fragment (control).

Results are shown in Figure 1. From Figure 1, it is evident that EGCG has the highest inhibiting activity among the five catechins.

Example 2

Telomerase inhibiting activity of EGCG

Telomerase activity in reaction solutions of 8 different EGCG concentrations ranging from 0.1 to 20 μM was measured in the same manner as described in Example 1 except that a primer, PS, was used at two different concentrations. Results are shown in Figure 2. A Dixon plot was plotted from the results in Figure 2, which gave a K_i value of about 100 nM (see Figures 2 and 3).

Example 3

Telomerase inhibiting activity of tea extract

Telomerase activity in reaction solutions containing powder sample 1 obtained in Production Example 1, powder sample 2 (a tea catechin extract: THEA-FLAN 90S, a trade name, a product of ITO EN, Ltd), and EGCG at different concentrations in the following ranges was measured in the same manner as described in Example 1.

Powder sample 1	0.30 to 1.00 $\mu\text{g/ml}$
Powder sample 2	0.10 to 0.30 $\mu\text{g/ml}$
EGCG	0.10 to 0.30 $\mu\text{g/ml}$

The composition of THEA-FLAN 90S is as follows:

Tea polyphenols	92% by weight
(-)-Epigallocatechin gallate	50% by weight
(-)-Epigallocatechin	0% by weight

(-)-Epicatechin gallate	13% by weight
(-)-Epicatechin	0% by weight
Caffein	0.5% by weight

Inhibiting activity was evaluated by computing the concentration of a sample which suppresses the amplification level of DNA in a control by 50% (IC_{50}).

Results are shown in Table 1.

Table 1 Telomerase inhibition, IC_{50} .

Sample	IC_{50}
1	0.88
2	0.24
EGCG	0.25

Example 4

Telomerase inhibiting activity in cells

The telomerase inhibiting activity of EGCG was assayed in monoblastoid leukemia U937 cells (American Type Culture Collection, ATCC) and colon adenocarcinoma HT29 cells.

An RPMI1640 medium (Nissui) supplemented with 10% fetal bovine serum (FBS) was used for U937 cells, and an RPMI1640 medium supplemented with 5% FBS and 5% fetal calf serum (FCS) was used for HT29 cells.

The cells were incubated in a 15 μ M EGCG solution for 2 hours and washed in PBS. The washed cells were suspended in an RPMI1640 medium (without serum) at a concentration of 2×10^6 cells/ml, then Streptolysin O (Sigma, 5 U/ml), TS primer (10 μ M), spermidine (1 mM), and Imipramine (50 μ M) were added, and the admixture was incubated at room temperature for 10 minutes. Streptolysin O is a substance which increases the permeability of a substance through the cell membrane,

and enables the TS primers and other substances to be incorporated into the cell.

The permeabilization reaction was stopped by adding an equal volume of RPMI1640 medium supplemented with 10% FBS, after which the cell suspension was further incubated for 1 hour to seal the cell membrane. The cells thus obtained, in which TS primer and other substances were incorporated, were incubated at room temperature for 1 hour to coat the cell membrane, and at the same time, to allow the intracellular telomerase reaction to progress. The cells were then washed twice with PBS, pelleted, and frozen for a TRAP assay to detect telomerase products.

Namely, the cells were washed with ice-cold PBS and suspended again in PBS to count the cells. This suspension was centrifuged, the resulting cell mass was suspended in a TRAP assay buffer, then the suspension was quick-frozen with liquid nitrogen. After melting, the suspension was allowed to stand in an ice bath for 30 minutes, then the resulting extract was centrifuged to obtain the supernatant as a cell extract. TS primer (344 nM), ACX primer (385 nM), 50 μ M dNTPs, T4g32 protein (Behringer-Manheim), an internal standard for PCR, TSNT (0.02 pM), and NT primer (385 nM) were added to a specified volume of the cell extract (corresponding to 200 to 1000 cells), then PCR was performed in the presence of Gene Taq DNA polymerase (2 U), i.e., (94°C, 40 seconds \rightarrow 50°C, 40 seconds \rightarrow 72°C, 60 seconds) x 35 cycles \rightarrow 72°C, 2 minutes, to obtain PCR products.

Base sequences of the primers used in this reaction are as follows.

ACX primer:

5'-GCGCGGCTTACCCTTACCCTTACCCTAACC-3' (SEQ ID NO: 4)

TSNT:

5'-AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3' (SEQ ID:
NO. 5)

NT primer:

5'-ATCGCTTCTCGGCCTTTT-3' (SEQ ID NO: 6)

The telomerase products thus obtained were resolved by polyacrylamide gel electrophoresis, after which DNA bands were stained with SYBR Green (Takara Shuzo) and detected by irradiation with a UV transilluminator. The intensity of each band was quantitatively analyzed using the NIH Image 1.60 software program and telomerase activity was expressed as the intensity of a sample band relative to that of the band corresponding to the ITAS fragment (control).

In the abovementioned PCR, a part elongated by telomerase was amplified using TS primer as the forward primer and ACX primer as the return primer. Further, the 36-bp internal standard (TSNT) and its own return primer (NT) were used as described by Kim et al. (Kim, N.W. and Wu, F., *Nucleic Acids Res.*, 25, 2595-2597, 1997).

Results are shown in Figure 4. The results showed that the treatment of the cells with EGCG markedly inhibited intracellular telomerase activity. Minor signals were also detected in the absence of TS primer. These signals were deemed to be derived from endogenous telomere sequences, or the like, and was similarly inhibited by the EGCG treatment.

Example 5

Mechanism of effect of EGCG on telomerase

The cells were treated with 15 μ M EGCG for 2 hours and washed with ice-cold PBS. The cell mass obtained by centrifugation was suspended in a TRAP assay buffer and the resulting suspension was quick-frozen with liquid nitrogen. After melting, the suspension was allowed to stand in an ice bath for 30 minutes, then the resulting extract was centrifuged to obtain the supernatant as a cell extract. A test compound, TS primer (50 ng), 50 μ M dNTPs, and T4g32 protein (Behringer-Manheim) were added to a specified volume of the cell extract (corresponding to 200 to 1000 cells), and the admixture was incubated at 20°C for 30 minutes. After

reaction, CX primer (100 ng) was added to the reaction solution, then PCR was performed in the presence of Gene Taq DNA polymerase (2 U) and ITAS (10^{-18} g), i.e., (94°C, 40 seconds → 50°C, 40 seconds → 72°C, 60 seconds) x 30 cycles → 72°C, 2 minutes, to obtain PCR products. The PCR products thus obtained were resolved by polyacrylamide gel electrophoresis and the resulting DNA bands stained with SYBR Green (Takara Shuzo) were detected by irradiation with a UV transilluminator. The intensity of each band was quantitatively analyzed using the NIH Image 1.60 software program. Telomerase activity was expressed as the intensity of a sample band relative to that of the band corresponding to the ITAS fragment.

The abovementioned procedure was carried out for both U937 cells and HT29 cells. Results showed that the EGCG treatment of cells had no effect on telomerase activity, when tested in vitro because of the dilution effect during the solubilization of cells. This observation along with the results of Example 1, 2, and 4 revealed that EGCG directly and reversibly inhibited telomerase activity in the cells, and that this inhibition was not through the intracellular information transfer system (intracellular signaling pathway).

Example 6

U937 cells and HT29 cells were each subcultured on a medium with and without EGCG to study the effect of addition of EGCG on cell growth. The medium used was the same as used in Example 4.

Five subculture lines for U937 cells and nine subculture lines for HT29 cells were prepared. The first culture of each line was made by inoculating cells of each stock culture at a density of 5×10^5 cells per 10-cm dish. For each subculture, two lines were cultured on a medium without EGCG (control lines) and the rest of the lines were cultured on a medium supplemented with 15 μ M EGCG.

Cells were passaged, sampled and counted every four days. The incubation medium was freshly changed every day.

Results are shown in Figure 5 (U937 cells) and Figure 6 (HT29 cells).

Symbol ○ shows the control line cultured on a medium without EGCG. In Figure 5, symbols ●, ▲, and ■ show the lines cultured on a medium supplemented with 15 μ M EGCG. Cells of all the lines entered cell crisis at day 53 (●), day 44 (▲), and day 29 (■), and thereafter showed morphological changes similar to cell senescence. In Figure 6, both symbols ▲ and ● show the lines cultured on a medium supplemented with 15 μ M EGCG. Cells of both lines entered cell crisis at day 75 (▲) and day 57 (●), and thereafter showed morphological changes similar to cell senescence.

U937 cells and HT29 cells entered crisis approximately at PD25 and PD60, respectively, showing characteristic morphological changes (rounding up and detachment for HT29 cells and raggedness of the plasma membrane for U937 cells).

U937 cells died at PD40 and HT 29 cells died at PD70. PD is the number of cycles in which the cell population doubles during cell growth and is calculated by monitoring cell counts using a hemocytometer.

The form of the cells did not revert and was maintained when the cells with morphological changes were transferred and cultured on a medium without EGCG, which confirmed that the morphological changes were not temporary.

HT 29 cells from PD57 to PD60 in cell crisis were pooled and the genomic DNA was prepared by a salting-out/ethanol precipitation method (Stratagene). Further, integrity of the isolated genomic DNA was confirmed by gel electrophoresis (ethidium bromide staining).

The isolated genomic DNA (10 μ g) was digested with HinfI and RsaI and the resulting digests were subjected to Southern blotting by the ordinary method, after

which DNA fragments were detected using a TeloQuant assay kit (PharmMingen).

Results are shown in Figure 7. While cleavage sites recognized by restriction enzymes *HinfI* and *RsaI* are numerous in a normal genomic DNA, such cleavage sites do not exist in the subtelomere or telomere region. Accordingly, if a genomic DNA is digested with the abovementioned restriction enzymes, only the telomere region would remain undigested. This DNA fragment is called the Terminal Restriction Fragment (TRF) which can be detected by Southern blotting to analyze telomere lengths. TRFs of EGCG-treated or untreated HT29 cells obtained as mentioned above were detected using a TeloQuant assay kit. Figure 7 shows the results of densitometric analysis of the detected signals. It was observed that TRFs in the cells which entered crisis due to the EGCG treatment (●) were shortened by about 1.1 kb as compared to those in the untreated cells (○). Further, it was confirmed that successive EGCG treatment of HT29 cells caused telomere diminishment.

Further, analysis of DNA content of cells before entering crisis by the ordinary method using flowcytometry revealed a 50 to 100% and a 10 to 20% increase in the aneuploidy and cell cycle G2/M fractions, respectively, for both U937 cells and HT29 cells.

In conclusion, it is evident from these results that cell crisis to death was caused by intracellular telomerase inhibition by EGCG.

What is claimed is:

1. A telomerase inhibitor comprising a catechin as an effective component.
2. A telomerase inhibitor of claim 1 comprising a green tea extract containing catechins.
3. A telomerase inhibitor of claim 1 or 2 wherein the catechin is epigallocatechin gallate, epigallocatechin, epicatechin gallate, or epicatechin.
4. A telomerase inhibitor of claim 1, 2, or 3 further comprising pharmaceutically acceptable carriers or diluents.
5. A telomerase inhibitor of either one of claims 1 to 4 wherein the catechin content is 90 to 95% by weight.
6. A cancer prevention or anticancer agent comprising a catechin as an effective component.
7. A cancer prevention or anticancer agent of claim 6 comprising a green tea extract containing catechins.
8. A cancer preventing or anticancer agent of claim 6 or 7 wherein the catechin is epigallocatechin gallate, epigallocatechin, epicatechin gallate, or epicatechin.
9. A cancer prevention or anticancer agent of claim 6, 7, or 8 further comprising pharmaceutically acceptable carriers or diluents.
10. A cancer prevention or anticancer agent of either one of claims 6 to 9 wherein the catechin content is 90 to 95% by weight.
11. A method of inhibiting a telomerase activity comprising a step of contacting a telomerase inhibitor as claimed in any one of claims 1 to 5.
12. A method of preventing or treating cancer comprising a step of administering an effective amount of a cancer prevention or anticancer agent as claimed in any one of claims 6 to 10 to a person needing thereof.
13. Use of a catechin for production of a telomerase inhibitor.

14. Use of a catechin for production of a cancer prevention or anticancer agent.
15. A method of producing a telomerase inhibitor comprising a step of formulation of the telomerase inhibitor using a catechin as an effective ingredient.
16. A method of producing a cancer prevention or anticancer agent comprising a step of formulation of the cancer prevention or anticancer agent using a catechin as an effective ingredient.

14. Use of a catechin for production of a cancer prevention or anticancer agent.

15. A method of producing a telomerase inhibitor comprising a step of formulation of the telomerase inhibitor using a catechin as an effective ingredient.

16. A method of producing a cancer prevention or anticancer agent comprising a step of formulation of the cancer prevention or anticancer agent using a catechin as an effective ingredient.

Catechins, known to be components of tea, can inhibit the enzyme activity of telomerase, an enzyme that synthesizes the telomeric DNA which is responsible for stabilizing the chromosome during cell growth. This telomerase inhibiting activity showed the usefulness of catechins as a cancer prevention agent, an anticancer agent, or a cancer retardation agent, or the like.

Fig.1




Fig.2




Fig.3




Fig.4




Fig.5




Fig.6





Fig.7



DECLARATION AND POWER OF ATTORNEY - USA PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the

invention entitled TELOMERASE INHIBITOR

the specification of which:

- (a) ☒ is attached hereto; or
- (b) ☐ was filed on _____ as ☐ Application
No. 0 / _____ or ☐ Express Mail No., as Application
No. not yet known _____ and was amended on
_____ (if applicable); or
- (c) ☐ was described and claimed in PCT International Application No.
_____ filed on
_____ and as amended under PCT Article 19 on
_____ (if any) and/or under PCT Article 34 on
_____ (if any).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent, design or inventor's certificate or any PCT international application(s) listed below and have also identified below any foreign application(s) for patent, design or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed for the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 U.S.C. § 119	
Japan	361282/1997	26, Dec., 1997	<input checked="" type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:


Prior U.S.A. Application(S)

Application No.: _____ Filing Date: _____ Status: _____

POWER OF ATTORNEY: I hereby appoint the registrants of Knobbe, Martens, Olson & Bear, LLP, 620 Newport Center Drive, Sixteenth Floor, Newport Beach, California 92660, Telephone (949) 760-0404, **Customer No. 20,995.**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Takashi TSURUO


Inventor's signature  Day 24 Month November Year 1998

Residence (prefecture and country only): Tokyo, Japan

Citizenship: Japanese

Post Office Address: 3-36-6, Miyasaka, Setagaya-ku, Tokyo, Japan

Full name of second inventor: Naasani IMAD


Inventor's signature  Day 24 Month November Year 1998

Residence (prefecture and country only): Tokyo, Japan

Citizenship: Syrian

Post Office Address: 2-6-2-301, Higashiikebukuro, Toshima-ku, Tokyo, Japan

Full name of third inventor: Hiroyuki SEIMIYA

Inventor's signature  Day 24 Month November Year 1998

Residence (prefecture and country only): Tokyo, Japan

Citizenship: Japanese

Post Office Address: 4-24-10-602, Towa, Adachi-ku, Tokyo, Japan

Full name of fourth inventor: Haruo SUGANO

Inventor's signature [Signature] Day 24 Month November Year 1998Residence (prefecture and country only): Tokyo, JapanCitizenship: JapanesePost Office Address: 4-8-13, Minamiogikubo, Suginami-ku, Tokyo, Japan

Full name of fifth inventor: _____

Inventor's signature _____ Day _____ Month _____ Year _____

Residence (prefecture and country only): _____

Citizenship: _____

Post Office Address: _____

Full name of sixth inventor: _____

Inventor's signature _____ Day _____ Month _____ Year _____

Residence (prefecture and country only): _____

Citizenship: _____

Post Office Address: _____

Full name of seventh inventor: _____

Inventor's signature _____ Day _____ Month _____ Year _____

Residence (prefecture and country only): _____

Citizenship: _____

Post Office Address: _____

Full name of eighth inventor: _____

Inventor's signature _____ Day _____ Month _____ Year _____

Residence (prefecture and country only): _____

Citizenship: _____

Post Office Address: _____

Send Correspondence To:

KNOBBE, MARTENS, OLSON & BEAR, LLP

Customer No. 20,995

PF-3.8

SEQUENCE LISTING

<110> Tsuruo, Takashi
 Imad, Naasani
 Seimiya, Hiroyuki
 Sugano, Haruo

<120> Telomerase Inhibitor

<130> WAKAB37.001AUS

<140> Unknown

<141> 1998-12-28

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 18

<212> DNA

<213> Unknow

<400> 1

aatccgtcga gcagagtt

18

<210> 2

<211> 28

<212> DNA

<213> Unknow

<400> 2

gtgcccttaa cccttaccct taccctaa

28

<210> 3

<211> 151

<212> DNA

<213> Unknow

<400> 3

aatcctgtcg agcagagttg tgaatgaggc cttcgaggct ctgaagagaa gcaccctgct
 60

caaccccaac cagcggctgc ctaaggtgga gatcctgcgc agtgccatcc agtacattga
 120

gcgcctatta gggtaagggt aagggttaagg g
 151

<210> 4

<211> 30
<212> DNA
<213> Unknow

<400> 4
gcgcggctta cccttaccct taccctaacc
30

<210> 5
<211> 36
<212> DNA
<213> Unknow

<400> 5
aatccgtcga gcagagttaa aaggccgaga agcgat
36

<210> 6
<211> 18
<212> DNA
<213> Unknow

<400> 6
atcgcttctc ggcctttt
18

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171